Sir Pascal Soriot turned down a near £70bn Pfizer offer in 2014, a gamble that paid off as AstraZeneca’s share now trades near £128 and its £207bn market cap eclipses the former bidder.

The company doubled its R&D spend, allocating $15bn to China and $50bn to the United States, while adding a $39bn Alexion acquisition to its rare‑disease pipeline. A mid‑stage weight‑loss trial and a $6.1bn lung‑cancer drug bolster the portfolio, and the firm aims to launch 20 new medicines by 2030.

Geopolitical pressure from U.S. lawmakers could throttle Chinese‑origin drug approvals, raising uncertainty for a portfolio that relies heavily on China‑developed molecules. A recent heart‑disease trial failure knocked the share price sharply, and the expiration of three blockbuster patents opens roughly $20bn of sales to generics.

AstraZeneca’s 24% R&D spend (about $14.2bn) underlines the company’s commitment to innovation, but investors must weigh the risk of regulatory shifts in China and the U.S. against the upside of a growing pipeline. The valuation hinges on successful approvals and market entry under tightening political scrutiny.